Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 4/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.49 |
| ▸ | CCKBR | P32239 | 4/20 | 0.48 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.48 |
| ▸ | TUBB | P07437 | 1/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29476447 | 1.00 | MC4R (0.50) | MC4RC5AR1KISS1RCCKBRTUBB4A | |
| SCHEMBL29517075 | 0.95 | C5AR1 (0.54) | MC4RC5AR1TUBB4ATUBBTUBA3C | |
| SCHEMBL30510367 | 0.95 | MC4R (0.52) | MC4RC5AR1KISS1RCCKBRCCKAR | |
| SCHEMBL31555133 | 0.94 | MC4R (0.52) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL29419493 | 0.94 | MC4R (0.52) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL29419550 | 0.94 | MC4R (0.52) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL30118069 | 0.94 | C5AR1 (0.52) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL29666221 | 0.94 | C5AR1 (0.52) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL29476562 | 0.93 | MC4R (0.50) | MC4RC5AR1KISS1RTUBB4ATUBB | |
| SCHEMBL29476617 | 0.93 | MC4R (0.50) | MC4RC5AR1KISS1RTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | claimed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | claimed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-11793746-B2 | Intense skin hydration systems and methods | ZAVERI CHANDA (US) | 2023-10-24 | — | — | US | claimed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | claimed |
| US-20220105024-A1 | Intense Skin Hydration Systems and Methods | ZAVERI CHANDA (US) | 2022-04-07 | — | — | US | claimed |
| EP-3977978-A1 | INTENSE SKIN HYDRATION SYSTEMS AND METHODS | Zaveri, Chanda (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114259417-A | Potent skin hydrating system and method | C·扎维拉 | 2022-04-01 | — | — | CN | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20220105024-A1 | Intense Skin Hydration Systems and Methods | ZAVERI CHANDA (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3977978-A1 | INTENSE SKIN HYDRATION SYSTEMS AND METHODS | Zaveri, Chanda (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114259417-A | Potent skin hydrating system and method | C·扎维拉 | 2022-04-01 | — | — | CN | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | MC4R 1/4885C5AR1 2625/4885KISS1R 75/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | MC4R 8/4885C5AR1 1092/4885KISS1R 417/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | MC4R 1/4885C5AR1 607/4885KISS1R 155/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | MC4R 4/4885C5AR1 72/4885KISS1R 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.